Skip to main content

Company Profile for DBV Technologies

DBV Technologies is the only company in the world whose products are designed to epicutaneously deliver on intact skin — via an epicutaneous patch — allergens for Epicutaneous Immunotherapy (EPIT) against food allergies or for allergy diagnosis. Using its proprietary patented delivery system VIASKIN®, DBV Technologies’ approach is to deliver biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. VIASKIN® is a non-invasive delivery system that utilizes electrostatic forces to present and deliver active compounds to the epidermis of the skin, without breaking the basement membrane (blood-skin barrier). As presented compounds, such as allergens, do not cross the blood-skin barrier, the risk of anaphylactic shock in allergic patients is dramatically reduced.

Company:

DBV Technologies

Headquarters Address:

Green Square - Bâtiment D 80/84 rue des Meuniers
Bagneaux 92220
France

Main Telephone:

+33 (0)1 55 42 78 78

Website:

http://www.dbv-technologies.com/en

Ticker/ISIN:

DBV(BOURSE)/FR0010417345

Type of Organization:

Public
IRPR

Industry:

Biotechnology

Earnings Release Dates:

1st Quarter: April 15, 2013

3rd Quarter: October 15, 2013

Key Executives:

CEO: Pierre-Henri Benhamou

CFO: David Schilansky

Co-Founder, CIO: Bertrand Dupont

Public Relations

Contact:

Ronald Trahan

Phone:

5083594005

Email:

rctrahan@ronaldtrahan.com

Investor Relations

Contact:

NewCap IR

Phone:

+33 1 84 16 29 01

Email:

dbv@newcap.fr

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.